Stay updated with breaking news from Comprehensive Breast Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.
No established standard of care currently exists after spread to the lymph nodes.
A planned 5-year trip in the United States coupled with a thirst for knowledge turned into a lifetime of surgical oncology accomplishments for Eleftherios “Terry” Mamounas, MD, MPH.
When neoadjuvant chemotherapy turns positive lymph nodes negative, 5-year survival outcomes are the same whether patients have regional nodal irradiation or not.
For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase the risk of disease recurrence or death five years after surgery, according to results from the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.